Voxelotor
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 223 publications
Dalcetrapib decreases red blood cell sickling propensity in sickle cell disease.
Journal: Clinical hemorheology and microcirculation
Published: August 12, 2026
HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities.
Journal: American journal of hematology
Published: July 06, 2026
Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.
Journal: Journal of managed care & specialty pharmacy
Published: June 24, 2026
Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.
Journal: The American journal of the medical sciences
Published: June 17, 2026
GBT1118 voxelotor analog improves skeletal muscle function, phenotype and significantly reduced serum myopathy biomarker GDF15 in sickle cell disease mice.
Journal: Biochemical and biophysical research communications
Published: May 08, 2026
Discontinued therapies for sickle cell disease: status and future directions.
Journal: Expert opinion on investigational drugs
Published: April 20, 2026
Real-world US Experience with Voxelotor for Sickle Cell Disease: A Plain Language Summary of the RETRO and PROSPECT studies.
Journal: Therapeutic advances in hematology
Published: April 20, 2026
In vitro effects of voxelotor on red blood cell senescence and rheological behavior in sickle cell anemia.
Journal: Blood cells, molecules & diseases
Published: March 26, 2026
Impact of voxelotor discontinuation on patients with sickle cell disease.
Journal: British journal of haematology
Published: March 04, 2026
Optimizing the right time to start sickle cell therapies.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Last Updated: 09/26/2026